RYTM - Rhythm Pharmaceuticals GAAP EPS of -$0.76 in-line revenue of $22.5M beats by $0.32M
2023-11-07 07:08:17 ET
More on Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals Q3 2023 Earnings Preview
- Rhythm’s obesity therapy granted EU backing for orphan designation
- Seeking Alpha’s Quant Rating on Rhythm Pharmaceuticals
For further details see:
Rhythm Pharmaceuticals GAAP EPS of -$0.76 in-line, revenue of $22.5M beats by $0.32M